Nasdaq ardx.

Ardelyx (NASDAQ: ARDX) stock is climbing today after the U.S. Food and Drug Administration ( FDA) approved the firm’s treatment for excessive phosphate levels in kidney disease patients. Shares ...WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Mar 2, 2023 · Ardelyx (ARDX) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.31 per share a year ago. These figures are ...

Find the latest historical data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com. ARDX U.S.: Nasdaq Ardelyx Inc. Watch list NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 4:07 p.m. EST Real time quote $ 4.7615 0.00 0.03% After Hours Volume: 89.07K...Ardelyx, Inc. Common Stock (ARDX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

ARDELYX INC ( ARDX) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 100% based on the firm’s underlying fundamentals and the stock’s ...

Shares of Ardelyx (NASDAQ: ARDX) were up 13.2% as of 2:30 p.m. ET Wednesday after the U.S. Food and Drug Administration (FDA) approved its first-in-class chronic kidney disease drug. In a press ...Ardelyx ( NASDAQ: ARDX) shares spiked ~10% on Tuesday after the developer of gastrointestinal and cardiorenal therapies soundly beat Wall Street expectations with its Q3 2023 financials, thanks ...Ardelyx Inc (NASDAQ: ARDX) Ardelyx is a biotech penny stock which already has a successful product on the market . Ibsrela (tenapanor) is a drug that was introduced by the company in March 2022. It is used …Find the latest historical data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.ARDELYX INC ( ARDX) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 100% based on the firm’s underlying fundamentals and the stock’s ...

Shares of Ardelyx ( ARDX 3.20%) were down more than 12% as of 3:30 p.m. on Wednesday. The healthcare company, which has a chronic kidney disease (CKD) drug that is awaiting approval later this ...

Ardelyx ( NASDAQ: ARDX) shares spiked ~10% on Tuesday after the developer of gastrointestinal and cardiorenal therapies soundly beat Wall Street expectations with its Q3 2023 financials, thanks ...

WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...About Nasdaq Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software, and services enables clients ...Dec 3, 2023 · Ardelyx (NASDAQ:ARDX – Get Free Report)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a report released on Friday, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Wedbush’s price objective would suggest a potential upside of 89.08% from the company’s previous close. Several other ... Ardelyx, Inc. (NASDAQ:ARDX) has gained about 353% over the past 12 months. As of the end of the first quarter of 2023, 20 hedge funds tracked by Insider Monkey were long Ardelyx, Inc. (NASDAQ:ARDX ...designer491. Shares of Ardelyx ( NASDAQ: ARDX) were down 17% in afternoon trading Wednesday ahead of an expected FDA decision on its kidney disease treatment candidate Xphozah and amid a market ...

Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates Zacks - Wed May 3, 4:15PM CDT . Ardelyx (ARDX) delivered earnings and revenue surprises of -18.18% and 12.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?Nov 6, 2023 · WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ... NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...Discover historical prices for ARDX stock on Yahoo Finance. View daily, weekly or monthly format back to when Ardelyx, Inc. stock was issued.WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...08 Jun, 2020, 16:01 ET. FREMONT, Calif., June 8, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX ), a specialized biopharmaceutical company focused on developing innovative first-in-class ...

Ardelyx (NASDAQ:ARDX), a biotech innovator, is arguably one of the best picks among penny stocks to buy. Its powerful portfolio, featuring IBSRELA for IBS-C and XPHOZAH for chronic kidney disease ...

Ardelyx (NASDAQ:ARDX) is a great speculative biotech play to look into. Why is that? That's because despite its potential with two drugs in the pipeline, the stock is still trading with a very low ...Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript (Insider Monkey) Oct-31-23 11:15PM Q3 2023 Ardelyx Inc Earnings Call (Thomson Reuters StreetEvents) +9.12%. 05:09PM Why Ardelyx Stock Soared Today (Motley Fool) 08:40AM Ardelyx (ARDX) Q3 Earnings and Revenues Top Estimates ...Shares of Ardelyx ( ARDX 3.20%) were down more than 12% as of 3:30 p.m. on Wednesday. The healthcare company, which has a chronic kidney disease (CKD) drug that is awaiting approval later this ...Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher Dec 02. Ardelyx Announces Launching of IBSRELA® Second Quarter of 2022 Dec 01. Insider notifies of intention to sell stock Nov 19. Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.20 loss in 3Q 2020)Nov 17, 2023 · ARDELYX INC ( ARDX) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 100% based on the firm’s underlying fundamentals and the stock’s ... Track Ardelyx Inc (ARDX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable ...Nov 16, 2023 · Ardelyx Inc (NASDAQ:ARDX) showed a performance of -1.41% in past 30-days. Number of shares sold short was 36.47 million shares which calculate 4.09 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $9.64 to the stock, which implies a rise of 59.96% to its recent value today. NVIDIA Corporation Common Stock. $439.77 -0.64 -0.15%. VFS. VinFast Auto Ltd. Ordinary Shares. $8.11 +0.06 +0.75%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours ...Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...

WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved XPHOZAH ...

Find the latest news headlines from Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.

WALTHAM, Mass., Feb. 2, 2023 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on January 27, 2023, the compensation committee of the company's …Sep 28, 2023 · WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ... Ardelyx, Inc. Common Stock (ARDX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Ardelyx (NASDAQ: ARDX), a biotech innovator, is arguably one of the best picks among penny stocks to buy.Its powerful portfolio, featuring IBSRELA for IBS-C and XPHOZAH for chronic kidney disease ...Analysts have provided the following ratings for Ardelyx (NASDAQ:ARDX) within the last quarter: According to 5 analyst offering 12-month price targets in the last 3 …WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Find the latest news headlines from Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.The put contract at the $4.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $4.00, but will …WALTHAM, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...08 Jun, 2020, 16:01 ET. FREMONT, Calif., June 8, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX ), a specialized biopharmaceutical company focused on developing innovative first-in-class ...Stock analysis for Ardelyx Inc (ARDX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.(NASDAQ: ARDX) Ardelyx currently has 232,137,709 outstanding shares. With Ardelyx stock trading at $4.51 per share, the total value of Ardelyx stock (market …

The FDA approved Ardelyx Inc's (NASDAQ:ARDX) Xphozah (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD ...Like Altisource, Ardelyx (NASDAQ:ARDX) is another stock that has performed very well during a time that has been tough for stocks overall.Shares in this pharma firm are up more than fourfold over ...Ardelyx Stock (NASDAQ:ARDX), Short Interest Report. Short interest for Ardelyx gives investors a sense of the degree to which investors are betting on the decline of Ardelyx's stock.Instagram:https://instagram. wtai etfhnoi nasdaqnyse ms comparenio options The bid-ask spread can indicate a stock's liquidity, which is how easy it is to buy and sell in the marketplace. Often, a smaller spread suggests higher ...Ardelyx, Inc. (NASDAQ:ARDX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts.The analysts have sharply increased their revenue ... federal realty inv. trustbest swing trading course Ardelyx (NASDAQ:ARDX – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research report issued on Friday, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Wedbush’s target price points to a potential upside of 89.08% from the stock’s current price. A number of […] best mid cap companies Analysts have provided the following ratings for Ardelyx (NASDAQ:ARDX) within the last quarter: According to 5 analyst offering 12-month price targets in the last 3 months, Ardelyx has an average ...Ardelyx (ARDX) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.14 per share a year ago.WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...